Cost of Intralesional Collagenase Clostridium Histiolyticum Therapy Versus Surgery for the Management of Peyronie's Disease: A Claims-Based Analysis (2009–2019)

Background: Collagenase Clostridium histolyticum (CCH), which was approved by the FDA for the treatment of Peyronie's disease (PD) in 2013, may obviate the need for surgery but its historically high cost must be considered when offering CCH vs surgical intervention to affected patients. Aim: To comp...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Eric L. Walton, MD, Timothy P. Quinn, MD, Evan Mulloy, MD, Dattatraya Patil, MBBS, MPH, Akanksha Mehta, MD, MS
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Oxford University Press 2022-06-01
سلاسل:	Sexual Medicine
الموضوعات:	Peyronie's Disease Cost Analysis Intralesional Collagenase Surgical Plication Plaque Grafting
الوصول للمادة أونلاين:	http://www.sciencedirect.com/science/article/pii/S2050116122000319
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!